로고 로고

About us

  • 홈버튼
  • About us
  • Our History

Our History

  • 2024

    • MAY

      Out-licensing Agreement with KSBL (SNA-001, Global region)

      Fast Track Designation (SNB-101, Small cell lung cancer, FDA)

      Orphan Drug Designation (SNB-101, Small cell lung cancer, EMA)

    • FEB

      Orphan Drug Designation (SNB-101, Pancreatic cancer, FDA)

  • 2023

    • SEP

      Phase 2 IND approval (SNB-101, Solid tumor, Korea)

    • JUL

      Orphan Drug Desingation (SNB-101, Small cell lung cancer, FDA)

  • 2022

    • DEC

      Out-licensing Agreement with Boryung (SNA-001, Korea region)

  • 2021

    • FEB

      Out-licensing Agreement with Boryung (SNB-101, Korea region)

  • 2020

    • JUN

      Phase 1 IND clearance (SNB-101, Solid tumor, FDA)

    • JAN

      Granted from NCI (NCL, Nanomedicine Characterization Lab)

  • 2017

    • MAY

      Foundation

TOP